Junyi Wang
Novartis
4 Papers
Junyi Wang is an academic researcher from Novartis. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria.
Michihiro Hide,Hae-Sim Park,Atsuyuki Igarashi,Young Min Ye,Tae-Bum Kim,Akiko Yagami,Joo-Young Roh,Jae Hyun Lee,Yuko Chinuki,Sang Woong Youn,Soo Keol Lee,Naoko Inomata,Jeong Hee Choi,Atsushi Fukunaga,Junyi Wang,Soichiro Matsushima,Steve Greenberg,Sam Khalil +17 more
TL;DR: The POLARIS study demonstrates that omalizumab is an efficacious and well-tolerated add-on therapy in Japanese and Korean H1AH-refractory patients with CSU.
60
Efficacy and safety of omalizumab for the treatment of refractory chronic spontaneous urticaria in Japanese patients: Subgroup analysis of the phase 3 POLARIS study.
Michihiro Hide,Atsuyuki Igarashi,Akiko Yagami,Yuko Chinuki,Naoko Inomata,Atsushi Fukunaga,Guenther Kaiser,Junyi Wang,Soichiro Matsushima,Steven Greenberg,Sam Khalil +10 more
TL;DR: This subgroup analysis demonstrated that omalizumab is a well-tolerated, beneficial option for treatment of CSU in H1AH-refractory Japanese patients.
21
The Predictive Value of Serum Calcium on Heart Rate Variability and Cardiac Function in Type 2 Diabetes Patients
Junyi Wang,Zi-Long Xu,Kangkang Lv,Yingchun Ye,Deng Luo,Li Wan,F. Zhou,Ailin Yu,Shuo Wang,Jingcheng Liu,Ling Gao +10 more
TL;DR: The serum calcium level can be used for risk evaluation of declined HRV in T2DM patients even within the normocalcemic range and is associated with a lower CaA level and worse cardiac function.
Predictive Factors for Recurrence of Papillary Thyroid Carcinoma in Children and Adolescents
TL;DR: Patients with characteristics such as younger age at diagnosis, positive preoperative TSH, maximal tumor size >2 cm, lateral LNM, and number of LNM >5 may be considered for prophylactic or therapeutic dissection of additional metastatic LNs by high-volume surgeons to prevent and reduce the recurrence rate of patients during long-term follow-up.